RBC Bioscience Balance Sheet Health
Financial Health criteria checks 1/6
RBC Bioscience has a total shareholder equity of NT$240.7M and total debt of NT$470.4M, which brings its debt-to-equity ratio to 195.4%. Its total assets and total liabilities are NT$753.8M and NT$513.1M respectively. RBC Bioscience's EBIT is NT$14.5M making its interest coverage ratio 1.5. It has cash and short-term investments of NT$65.2M.
Key information
195.4%
Debt to equity ratio
NT$470.35m
Debt
Interest coverage ratio | 1.5x |
Cash | NT$65.18m |
Equity | NT$240.71m |
Total liabilities | NT$513.08m |
Total assets | NT$753.79m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6848's short term assets (NT$140.2M) exceed its short term liabilities (NT$99.8M).
Long Term Liabilities: 6848's short term assets (NT$140.2M) do not cover its long term liabilities (NT$413.3M).
Debt to Equity History and Analysis
Debt Level: 6848's net debt to equity ratio (168.3%) is considered high.
Reducing Debt: 6848's debt to equity ratio has increased from 56.1% to 195.4% over the past 5 years.
Debt Coverage: 6848's debt is not well covered by operating cash flow (2.8%).
Interest Coverage: 6848's interest payments on its debt are not well covered by EBIT (1.5x coverage).